Cytokine Therapies and Inhibitors: A Vibrant Pipeline and Active Approved Market
Mark C. Via
Cytokines have drawn immense interest from the pharmaceutical industry over the last two decades. Great effort has been devoted to finding ways to reproduce their effects—or to block their activity—in the quest to create novel drugs for cancer, infectious diseases, inflammatory and immune disorders, and myelosuppression. Cytokine Therapies and Inhibitors: A Vibrant Pipeline and Active Approved Market, a CHI Insight Pharma Report, takes a comprehensive look at the full range of cytokine therapies and inhibitors, from products in research and development to products already approved and marketed.
This report thoroughly evaluates the field of cytokines as it relates to drug development by providing:
- A description of cytokines and an explanation as to how they are classified
- In-depth coverage of approved and experimental cytokines and cytokine inhibitors, including late clinical research news on some of the most promising drugs in development
- Analysis of the interleukins, the interferons, the tumor necrosis factor superfamily, transforming growth factor-beta, the hematopoietic growth factors, and the chemokines, or chemotactic cytokines
- Discussion of efforts to develop improved versions of existing drugs
- Evaluation of the current and future markets for cytokine-based therapeutics
Recombinant forms of natural cytokines were among the early success stories of the biotech boom. Genetically engineered versions of interleukin-2, interferon-alfa and -beta, erythropoietin, and the colony-stimulating factors have now been available for years and remain profitable products for their manufacturers.
In all, Cytokine Therapies and Inhibitors: A Vibrant Pipeline and Active Approved Market examines more than 200 drugs and research programs, ranging from cytokines to cytokine variants and agonists, from the approved interleukin-2 drug Proleukin from Chiron/Novartis, for treating renal cell carcinoma, to the interferon-omega drug candidate now in Phase II trials by Intarcia Therapeutics, for treating hepatitis C virus. For example, one drug discussed, Multikine from CEL-SCI, just received approval in January to go into a Phase III trial to show that it can increase survival times for head and neck cancer patients. The drug already has been shown to be nontoxic in Phase II trials that also showed improvements in survival. The report also evaluates cytokine inhibitors, from Amgen’s interleukin-1 receptor antagonist Kineret, approved for treatment of rheumatoid arthritis to Abbott Laboratories’ interleukin-18 monoclonal antibody now in Phase I research for autoimmune disorders.
The market for cytokine-based therapeutics holds great promise. Sales in 2005 for 13 of the 35 cytokine drugs already approved amounted to more than $1 billion each. Centocor/Johnson & Johnson’s Remicade alone racked up sales of almost $3.5 billion in 2005. Perhaps the biggest market of all is anemia, where recombinant erythropoietin drugs boasted sales of more than $10 billion in 2005.
Cytokine Therapies and Inhibitors: A Vibrant Pipeline and Active Approved Market is an indispensable report for individuals directly involved in the research and development, licensing, or marketing of cytokine-based therapies.
About the Author
Mark C. Via, an editor at CTB International Publishing, has more than 13 years of experience writing and editing for pharmaceutical trade publications. He holds a BA in history from Williams College. Mr. Via has authored previous Cambridge Healthtech reports, including Kinase Therapeutics: A Wealth of Targets Sparks a Highly Active Market